Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Licensing deals
Biotech
US VC launches another biotech with China-licensed asset
Aditum is offering up to $1 billion biobucks to Mabwell for exclusive global licensing rights to a dual-target siRNA candidate.
Gabrielle Masson
Sep 17, 2025 10:30am
Novartis pens Monte Rosa molecular glue pact worth up to $5.7B
Sep 15, 2025 9:07am
Trump admin mulls 'severe restrictions' on new China drugs: NYT
Sep 10, 2025 9:16am
Novartis returns to Argo for $5B cardiovascular collab
Sep 3, 2025 9:15am
Servier hands Ideaya $210M upfront for ex-US rights to PKC asset
Sep 2, 2025 3:02pm
Novartis aims at alpha-synuclein again with $2.2B Arrowhead deal
Sep 2, 2025 9:55am
